No Data
Yifan Pharmaceutical: 2024 Annual Report
Yifan Pharmaceutical: 2024 Annual Report Summary
Yifan Pharmaceutical (002019.SZ): The relevant matters have a minor impact on the company's Business.
According to Gelonghui on April 16, Yifan Pharmaceutical (002019.SZ) stated on the interactive platform that the current anticipated impact of this matter on the company's business is relatively minor. In the future, the company will continue to monitor and assess its potential impact on the company's business.
Yifan Pharmaceutical Gets Drug Registration for Cancer, Post-Surgery Analgesic
Yifan Pharmaceutical (SZSE:002019 Investor Five-year Losses Grow to 40% as the Stock Sheds CN¥1.3b This Past Week
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Not Quite Adding Up
